Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
暂无分享,去创建一个
Carissa A. Sanchez | B. Reid | G. Longton | P. Galipeau | C. Sanchez | L. J. Prevo | G M Longton | B J Reid | P C Galipeau | C A Sanchez | L J Prevo
[1] M. Emond,et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.
[2] P. Maxwell,et al. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. , 1998, British Journal of Cancer.
[3] M. Beckmann,et al. Frequent allele loss on 9p21–22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer , 1996, Genes, chromosomes & cancer.
[4] P. Blount,et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.
[5] B. Reid,et al. Barrett's esophagus: a model of human neoplastic progression. , 1994, Cold Spring Harbor symposia on quantitative biology.
[6] B. Reid,et al. p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.
[7] C. McConkey,et al. The rising trend in oesophageal adenocarcinoma and gastric cardia. , 1992, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[8] R. Sampliner,et al. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.
[9] G. Eastwood,et al. Cell proliferation in three types of Barrett's epithelium 1 , 1980, Gut.
[10] G. Thomas,et al. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.
[11] Patricia L. Blount,et al. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Reid,et al. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. , 1987, Gastroenterology.
[13] D. Levine. Management of dysplasia in the columnar-lined esophagus. , 1997, Gastroenterology clinics of North America.
[14] J B Wong,et al. A guide for surveillance of patients with Barrett's esophagus. , 1994, The American journal of gastroenterology.
[15] S. Hirohashi,et al. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. , 1992, Cancer research.
[16] G. Chejfec,et al. High grade dysplasia still is not an indication for surgery in patients with Barrett's esophagus: An update , 1998 .
[17] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[18] B. Reid,et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. , 1988, Gastroenterology.
[19] W. Hop,et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.
[20] O. Yoshida,et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. , 1998, Cancer research.
[21] J. Fraumeni,et al. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.
[22] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[23] W S Payne,et al. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.
[24] J. Fleiss. Statistical methods for rates and proportions , 1974 .
[25] Carissa A. Sanchez,et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. , 1991, Cancer research.
[26] Carissa A. Sanchez,et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.
[27] N. Walker,et al. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.
[28] J. Minna,et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.
[29] R. Sampliner,et al. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997, The American journal of gastroenterology.
[30] W G Doos,et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.
[31] D. Lane,et al. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. , 1992, Gastroenterology.
[32] Patricia L. Blount,et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.
[33] K Y Liang,et al. Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.
[34] J. Fraumeni,et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.
[35] M. Berenson,et al. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). , 1978, Gastroenterology.
[36] P. Goodfellow,et al. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. , 1996, Cancer research.
[37] D. Wong,et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.
[38] G. Thomas,et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.
[39] G. Peters,et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.
[40] Carissa A. Sanchez,et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. , 1993, Gastroenterology.
[41] J. Abraham,et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. , 1994, Oncogene.
[42] B. Vogelstein,et al. Clonal origin of bladder cancer. , 1992, The New England journal of medicine.
[43] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[44] C. Purdie,et al. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. , 1993, Oncogene.
[45] J. Peters,et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. , 1994, The Journal of thoracic and cardiovascular surgery.
[46] S. Re,et al. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .
[47] C. Hsieh,et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. , 1998, Gastroenterology.
[48] J. V. van Sandick,et al. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus , 2000, The Journal of pathology.
[49] B. Reid,et al. Barrett's esophagus and esophageal adenocarcinoma. , 1991, Gastroenterology clinics of North America.
[50] P. Radice,et al. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. , 1995, Cancer research.
[51] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[52] Wong Rk,et al. Barrett's esophagus. Natural history, incidence, etiology, and complications. , 1991 .
[53] Carissa A. Sanchez,et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[54] B. Reid,et al. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. , 1999, Genome research.
[55] Jing Yin,et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. , 1994, Cancer research.
[56] Flow-cytometric DNA content analysis of esophageal squamous cell carcinomas. , 1991, Gastroenterology.
[57] R. Sampliner,et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. , 1989, Gastroenterology.
[58] B. Reid,et al. Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[59] N. Shaheen,et al. Surveillance for Barrett's esophagus: are we saving lives? , 1997, Gastroenterology.
[60] Carissa A. Sanchez,et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. , 1996, Oncogene.
[61] T. Wright. High‐grade dysplasia in Barrett's oesophagus , 1997, The British journal of surgery.
[62] Patricia L. Blount,et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .
[63] Johannes Gerdes,et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.
[64] E Gabrielson,et al. Genetic divergence in the clonal evolution of breast cancer. , 1996, Cancer research.
[65] G Van Belle,et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.
[66] R Montironi,et al. Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. , 1996, Human pathology.
[67] J. G. van den Tweel,et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.
[68] R. Sutton,et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. , 1998, British Journal of Cancer.
[69] Carissa A. Sanchez,et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. , 1994, Cancer research.
[70] W. Hong,et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. , 1993, Cancer research.
[71] Carissa A. Sanchez,et al. Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.